Phibro Animal Health Corporation and Rejuvenate Bio Announce Agreement to Develop Gene Therapy for Mitral Valve Disease in Dogs

TEANECK, NJ–(BUSINESS WIRE)–Phibro Animal Health Corporation (Nasdaq: PAHC) and Rejuvenate Bio, Inc. today announced a collaboration to develop and commercialize a gene therapy for mitral valve disease (MVD) in canines ( dogs).

The incidence of MVD varies widely, but is thought to be present in around 7% of all dogs and can be as high as 80% for some breeds such as Cavalier King Charles Spaniels. Rejuvenate Bio has received support from the American Cavalier King Charles Spaniel Club for this research.

MVD is caused by a malfunction of the mitral valve which allows blood to flow back from the lower chamber of the heart (ventricle) to the upper chamber (atrium). The condition often results in and is diagnosed by a characteristic ‘murmur’. The disease may have little or no outward effects at first, but over months or years it may progress to congestive heart failure and death.

Current therapies have been shown to slow the progression of MVD, but no therapy is available to stop the disease or reverse the damage. The goal of the collaboration between Phibro and Rejuvenate Bio is to develop and commercialize a new gene therapy with the aim of not only stopping MVD before it leads to heart failure, but also reversing all or part heart damage.

Thomas Zerzan, President of the Companion Animal Division at Phibro Animal Health, said, “We are confident that our collaboration with Rejuvenate Bio will achieve our goal of developing an effective gene therapy that will revolutionize the way veterinarians treat MVD. , adding years to the life of a dog that suffers from this disease.

Daniel Oliver, CEO of Rejuvenate Bio, said, “We are delighted to be working with Phibro to make the treatment of MVD a reality. We plan to apply for conditional approval as early as 2023. We see this as a first step in addressing many age-related illnesses that affect the animals we love.

The effort to develop a gene therapy for MVD is based on research and discoveries made in the lab at Harvard Medical School and the Wyss Institute by genetic scientist and startup founder George Church.

About Phibro Animal Health Corporation

Phibro Animal Health Corporation is a leading diversified global animal health and mineral nutrition company. We strive to be a trusted partner with livestock producers, farmers, veterinarians and consumers who raise or care for farm and companion animals by providing solutions to help them maintain and improve health. of their animals.

About Organic Rejuvenate

Rejuvenate Bio is a spin-out from Harvard’s Wyss Institute focused on reversing aging and eliminating age-related diseases. Rejuvenate Bio uses gene therapy, proprietary targets and tools to bring treatments to humans and dogs suffering from age-related diseases. The company is developing a pipeline of therapies with applications in heart and metabolic diseases in humans and dogs. The company raised Series A funding in 2021 led by Kendall Capital Partners, Digitalis Ventures, KdT Ventures and V Capital. Rejuvenate Bio is based in San Diego for more information visit

Boyd S. Abbott